<DOC>
	<DOCNO>NCT02187432</DOCNO>
	<brief_summary>EuroCYST initiative aim build large , well-characterized cohort Autosomal Dominant polyCYSTic Kidney Disease ( ADPKD ) subject followed longitudinal observational cohort study potential identify progression factor biomarkers , assess disease stage specific mortality , morbidity health care cost .</brief_summary>
	<brief_title>The Eurocyst Initiative : Building Network ADPKD Reference Centers Across Europe</brief_title>
	<detailed_description>The EuroCYST Initiative aim build network ADPKD reference center across Europe establish large-scale observational cohort ADPKD patient purpose study pathogenesis , rate disease progression , progression rate modifier , disease stage specific morbidity , mortality , health economic issue predictive value biomarkers ADPKD . Overall 1,100 patient enrol 14 study site across Europe follow least three year . The ADPKD reference center network across Europe observational cohort study enable European ADPKD researcher gain insight natural history , heterogeneity associate complication disease well affect live patient across Europe .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<criteria>Participants ≥ 18 year ; Clinical diagnosis ADPKD base kidney image family history ; Estimated Glomerular Filtration Rate ( eGFR ) ≥ 30 ml/min/1.73m2 ( Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI ) formula ) ; Provided write informed consent . Receiving chronic renal replacement therapy enrollment ( dialysis , allograft ) anticipate follow 12 month enrollment ; Participation clinical trial aim modify disease outcome one year less enrollment EuroCYST study ; New York Heart Association ( NYHA ) stadium IV .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>